摘要
探究盐酸西替利嗪和孟鲁司特钠治疗小儿过敏性鼻炎(AR)疗效及对外周血Th1/Th2平衡的影响。选取2023年7月至2023年10月于医院耳鼻喉科接受治疗的104例AR患儿,简单随机分为CET组和CET+MT组,每组各52例,CET组予以盐酸西替利嗪(CET)治疗,CET+MT组在CET组的基础上联合孟鲁司特钠(MT)治疗。比较两组患儿临床疗效和症状改善情况,过敏性疾病指标[血清总免疫球蛋白E(tIgE)、嗜酸性粒细胞(EOS)百分比]、鼻阻力、外周血1型辅助性T细胞(Th1)细胞因子[干扰素-γ(IFN-γ)]、Th2细胞因子[白细胞介素-4(IL-4)]、IFN-γ/IL-4和不良反应。CET+MT组临床有效率为98.08%,高于CET组的86.54%(P<0.05);治疗后,两组鼻部及咽部症状评分均下降(P<0.05),且治疗后CET+MT组低于CET组(P<0.05);治疗后,两组tIgE水平、EOS百分比、鼻阻力均下降(P<0.05),且治疗后CET+MT组低于CET组(P<0.05);治疗后,两组IL-4均下降(P<0.05),IFN-γ、IFN-γ/IL-4均上升(P<0.05),且治疗后组间比较差异具有统计学意义(P<0.05);两组不良反应率比较无显著性差异(P>0.05),症状均较轻微,停药后自动消失。盐酸西替利嗪联合孟鲁司特钠可有效提升AR患儿临床疗效,改善临床症状及鼻阻力,纠正Th1/Th2失衡,安全性好,适于临床应用。
To explore the efficacy of cetirizine hydrochloride and montelukast sodium in the treatment of children with allergic rhinitis(AR)and the effects on Th1/Th2 balance in peripheral blood,104 children with AR who received treatment in the ENT department of the hospital from July 2023 to October 2023 were randomly divided into CET group and CET+MT group,with 52 cases in each group.CET group was treated with cetirizine hydrochloride(CET),and CET+MT group was treated with montelukast sodium(MT)on the basis of CET group.The clinical efficacy and symptom improvement of the two groups were compared.Indicators of allergic disease[serum total immunoglobulin E(tlgE),eosinophils(EOS)percentage],nasal resistance,peripheral blood type 1 T helper cell(Th1)cytokine[interferon-(IFN-)],Th2 cytokine[interleukin-4(IL-4)],IFN-/IL-4,and adverse reactions were also compared.The clinical effective rate of CET+MT group was 98.08%,higher than that of CET group 86.54%(P<0.05).After treatment,the nasal and pharyngeal symptom scores of both groups were decreased(P<0.05),and CET+MT group was lower than CET group after treatment(P<0.05).After treatment,tlgE level,EOS percentage and nasal resistance of both groups were decreased(P<0.05),and CET+MT group was lower than CET group after treatment(P<0.05).After treatment,IL-4 decreased in both groups(P<0.05),IFN-and IFN-/IL-4 increased in both groups(P<0.05),and the difference between groups after treatment was statistically significant(P<0.05).There was no significant difference in the rate of adverse reactions between the two groups(P>0.05),and the symptoms were mild and disappeared automatically after drug withdrawal.Cetirizine hydrochloride combined with montelukast sodium can effectively improve clinical efficacy,improve clinical symptoms and nasal resistance,and correct Thi/Th2 imbalance in children with AR.It is safe and suitable for clinical application.
作者
余智荣
张慧
姜尚林
YU Zhirong;ZHANG Hui;JIANG Shanglin(Department of Pediatrics,Shantou Maternal and Child Health Hospital,Shantou 515000,China)
出处
《药物生物技术》
2024年第6期673-677,共5页
Pharmaceutical Biotechnology
关键词
过敏性鼻炎
儿童
盐酸西替利嗪
孟鲁司特钠
T淋巴细胞
不良反应
症状
Allergic rhinitis
Children
Cetirizine hydrochloride
Montelukast sodium
T lymphocytes
Adverse reactions
Symptom
